ARTICLE | Clinical News
Intrarosa regulatory update
November 17, 2016 10:45 PM UTC
FDA approved an NDA for Intrarosa prasterone from Endoceutics to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), in postmenopausal women. The once-daily vaginal in...
BCIQ Company Profiles